BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+13.48%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$644M
AUM Growth
+$644M
(+9.5%)
Cap. Flow
+$27.7M
Cap. Flow
% of AUM
4.3%
Top 10 Holdings %
Top 10 Hldgs %
67.17%
Holding
35
New
5
Increased
13
Reduced
7
Closed
1
Top Buys
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$27.6M |
| 2 |
Forte Biosciences
FBRX
|
$15.4M |
| 3 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$13.6M |
| 4 |
LOXO
Loxo Oncology, Inc
LOXO
|
$11.5M |
| 5 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
$8.79M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$27.5M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$25.9M |
| 3 |
IMDZ
Immune Design Corp.
IMDZ
|
$8.39M |
| 4 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$6.69M |
| 5 |
Fate Therapeutics
FATE
|
$5.03M |
Sector Composition
| 1 | Healthcare | 78.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.78M | 0.74% |
1,770,692
+230,369
| +15% | +$622K |
|
|
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $3.42M | 0.53% |
+300,000
| New | +$3.42M |
|
28
Corvus Pharmaceuticals
CRVS
$419M
| $3.32M | 0.52% |
+274,196
| New | +$3.32M |
|
|
RGLS
29
DELISTED
Regulus Therapeutics
RGLS
| $3.23M | 0.5% |
3,278,900
+2,655,900
| +426% | +$2.62M |
|
|
OREX
30
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $2.13M | 0.33% |
734,976
| – | – |
|
|
ANTH
31
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $1.63M | 0.25% |
1,006,507
-7,045,566
| -88% | -$3 |
|
32
Cassava Sciences
SAVA
$107M
| $1.34M | 0.21% |
325,508
-1,953,044
| -86% | +$4 |
|
|
33
Fate Therapeutics
FATE
$115M
| $1.27M | 0.2% |
391,386
-1,553,859
| -80% | -$5.03M |
|
|
IMDZ
34
DELISTED
Immune Design Corp.
IMDZ
| – | – |
-1,233,976
| Closed | -$8.39M |
|